We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Diagnostic Platform Helps Identify and Monitor Eye Diseases

By LabMedica International staff writers
Posted on 21 Sep 2009
A technology suite identifies all major categories of eye diseases and supports all ophthalmic and optometric specialties.

The devices capture more than 100,000 visual images per day, providing eye care professionals with critical details about the tissues and structures that lie deep inside the eye.

Carl Zeiss Meditec (Jena, Germany) placed more than 10,000 optical coherence tomography (OCT) platforms worldwide. More...
These units include the Cirrus HD-OCT, the Stratus OCT and the Visante OCT.

"From the time that we set out to develop the first OCT platform, we intended to revolutionize the ophthalmic diagnostic industry," said Carmen A. Puliafito, M.D., M.B.A., Dean of the Keck School of Medicine of the University of Southern California (USC; Los Angeles, CA, USA), and one of the pioneers of the technology. "OCT technology provides clinicians with images of the eye that no other platform can provide. It is an indispensable tool for the retina practice and pivotal for determining which patients to treat and which intervention to provide, whether pharmacologic or surgical. OCT is especially important to monitor the effectiveness of the new AMD [age-related macular degeneration] drugs that are entering the market."

Carl Zeiss Meditec continues to develop powerful software tools to maximize the efficiency and longevity of its OCT technology. New glaucoma and retina imaging applications for Cirrus HD-OCT provide the most detailed scan patterns and layer maps available for identifying retinal and glaucoma disease characteristics, and monitoring disease progression. Guided Progression Analysis (GPA) software for Stratus OCT accurately predicts a patient's stage of disease, rate of progression and risk of future vision loss by measuring statistically significant change.

Related Links:
Carl Zeiss Meditec
University of South Carolina



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Aspiration System
VACUSAFE
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Total Laboratory Automation Solution
SATLARS Mini T8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.